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The serum opacity reaction of Streptococcus pyogenes (Group A streptococci), 
first described by Ward and Rudd (1), is associated with a lipoproteinase which 
acts upon the ax-lipoprotein fraction of serum to produce a measurable opales- 
cence  (2-4).  Evidence of  the  antigenicity of streptococcal lipoproteinase in 
rabbits and in humans has been presented both by Krumwiede and by Rowen 
(2, 5).  Krumwiede found that sera of rabbits immunized with filtrates of an 
enzyme-producing strain grown in rabbit serum inhibited the serum opacity 
reaction  (SOR)  produced by that  strain.  Moreover, the  addition  of certain 
human sera or a  sample of human -y-globulln  to horse serum-enzyme mixtures 
was found to prevent the splitting of serum lipoprotein by streptococcal lipo- 
proteinase. Rowen demonstrated a  substance capable of inhibiting the opales- 
cence produced by fipoproteinase in the sera of 25-30 %  of adults tested, and 
suggested that this inhibitory substance might be antibody. 
Studies by Gooder (6), by K6hier (7), and from this laboratory (8) indicate a 
high  degree  of  association  between  lipoproteinase  production  and  certain 
serotypes of Group A  streptococci. Furthermore, strains of Group A  strepto- 
cocci which are difficult to type by the M-precipitin method are often good 
producers of lipoproteinase (6-8) 
An antigen of Group A streptococci exhibiting a  close association with cer- 
tain serotypes and produced by strains which are difficult to characterize pre- 
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cisely  by  currently  available  methods  might  provide  distinct  advantages  in 
the identification of streptococcal  strains.  Further  investigations into the anti- 
genicity  of  streptococcal lipoproteinase thus  seemed warranted.  Such investi- 
gations are described in this paper,  which demonstrates  the existence of many 
antigenically  distinct  streptococcal  lipoproteinases,  each  of  which  shows 
remarkable  specificity for  a  certain group  of  strains. 
Methods 
Group A Streptococcal Strains Used.--All strains used in these experiments were examined 
for group, M  type, T-agglutination pattern, and (when indicated) the 28 R  antigen by stand- 
ard techniques (9, 10, 16). 
The following arbitrarily arranged groups of strains were tested with the various SOR 
inhibitory antisera produced: 
Group I 
Strain  M  T  R  Source 
CDC2  2  2  --  CDC No. T2/44/Rb4/71/3 
3497  4  4  --  Minneapolis 
CDC8  8  8/25/imp. 19  --  CDC No. C265/64/1 
6131  25  8/25/imp. 19  --  Colindale 8306 
RL2415  NT  8/25/imp. 19  --  Red Lake 
AN730  NT  8/25/imp. 19  --  St. Patti 
5972  NT  8/25/imp. 19  --  Minneapolis 
6122  9  9  ~  Colindale 8316 
CDCll  11  11  --  CDC No. Tll/54/3 
AN124  NT  11  --  St. Paul 
AN507  NT  11  --  St. Paul 
RL3124  N'T  12  ~  Red Lake 
CDC13  13  3/13/B3264  --  CDC No. T13/51/5 
AN502  NT  3/13/B3264  --  St. Paul 
3221  22  22  --  Minneapolis 
CDC28  28  28  28  CDC No. T28/150A/3 
AN632  NT  28  --  St. Paul 
AN261  NT  28  ~  St. Paul 
RI~034  NT  5/27/44  --  Red Lake 
CV549  NT  5/27/44  --  Red Lake 
AN378  48  4  28  St. Paul 
5856  49  14  --  Rockefeller University B737/71/1 
Group II 
Strain  M  T  R  Source 
6082  2  2  --  Minneapolis 
6119  4  4  --  Colindalc 8326 
4412  8  8/25/imp. 19  --  Minneapolis 
CDC25  25  8/25/imp. 19  --  CDC No. B3460P 
6128  NT  8/25/imp. 19  --  Colindale 100109 Strain 
CV387 
6O93 
CV725A 
AN315 
RL3203 
6192 
6125 
CDC22 
6133 
6241 
5937 
AN586 
RL3146 
6016 
6257 
Strain 
3536 
AN1048 
CV677A 
RL1533 
RL2717 
AN626 
AN628 
3015 
5395 
5396 
CV595B 
6123 
CV722 
AN441 
RL2862 
RLl128 
RL2786 
6270 
6271 
6272 
RL609 
AN989 
6031 
RL3010B 
CDC27 
CV822B 
6263 
N. Scheuring 
6475 
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M  T  R  Source 
NT  8/25/imp. 19  --  Red Lake 
NT  9  --  Colindale T9/101/4 
NT  11  --  Red Lake 
NT  11/B3264  --  St. Paul 
NT  12  --  Red Lake 
NT  12/]33264  --  St. Paul 
13  3/13/B3264  --  Colindale 8314 
22  22  --  CDC No. T22/I17 
NT  28  28  Colindale 8308 
NT  28  --  St. Paul 
NT  5/27/44  --  Minneapolis 
NT  5/27/44  --  St. Paul 
NT  5/27/44  --  Red Lake 
48  4  28  Colindale C510/100b/1 
49  14  --  Prague,  Rockefeller  University  A810 
Group III 
M  T  R  Source 
NT  2  --  Minneapolis 
2  2  28  St. Paul 
BIT  8/25/imp. 19  --  Red Lake 
NT  8/25/imp.  19  --  Red Lake 
NT  8/25/imp. 19  --  Red Lake 
NT  8/25/imp. 19  --  St. Paul 
NT  8/25/imp. 19  --  St. Paul 
NT  9  b  Minneapolis 
NT  9  --  Minneapolis 
NT  9  ~  Minneapolis 
NT  11  --  Red Lake 
NT  11  --  Colindale 8318 
NT  11  --  Red Lake 
NT  11  --  St. Paul 
NT  12  --  Red Lake 
NT  12  b  Red Lake 
NT  12  --  Red Lake 
NT  28  28  Rockefeller University B574 
NT  28  28  Rockefeller University B96O 
NT  28  28  Rockefeller University A674 
NT  28  --  Red Lake 
NT  28  --  St. Paul 
NT  28  --  Minneapolis 
NT  5/27/44  --  Red Lake 
27  5/27/44  --  Type 27--Dr. Lancefield 
NT  5/27/44  --  Red Lake 
49  14  --  Chile, Rockefeller University B766 
NT  14  --  Minneapolis 
NT  14  --  Alabama, Dillon 223S 1016  SERUM  OPACITY REACTION  OF  STREPTOCOCCUS PYOGENES 
Preparation of Vaccines.--Lipoproteinase-producing strains were inoculated into 1.6 liters 
of Todd-Hewitt broth and incubated at 37°C for 16-18 hr. The cells were collected by eentrif- 
ugation,  washed three times in 0.9% saline,  and resuspended in 25  ml  saline.  3 ml of 1% 
merthiolate were added to the suspension. After disruption in a  Midde disintegrator, the 
fraction containing ceil  walls and  membranes was coilected by centrifugation at  20,000  g. 
The cell wall-membrane fraction was washed twice in saline and resuspended in 100 ml saline. 
This suspension was plated to assure absence of viable streptococci and was then used as a 
vaccine. 0.2  ml of vaccine was incubated overnight at 37"C in 1.0 ml horse serum to make 
certain that the vaccine contained active enzyme. 
Immunisation.--Albino  rabbits were immunized intravenously  with the vaccine according 
to the following schedule: 5 days after an initial intravenous injection of 0.5 ral of vaccine, the 
rabbit was reinjected on 3 consecutive days and then rested for 4 clays before the next series 
of three injections. After the first four injections of 0.5 ml, the dosage was increased to 1.0 
ml of vaccine if tolerated by the animal. After 15-18  total injections, rabbits were rested for 
5 days and bled. Their serum was tested for ability to inhibit the SOR of the vaccine strain. 
TABLE I 
Mahod for Measurement of SOR lnkibition 
Tube  ...............................................  I  II  III  IV 
Enzyme containing dilution, m/  ............ 
Saline, m/  ............................... 
Immune rabbit serum, m/  ................. 
Nonimmune rabbit serum, m/  ............. 
Horse serum, m/  ......................... 
0.2 
0.2 
1.0 
0.2 
0.2 
1.0 
0.2 
0.2 
1.0 
0.2 
0.2 
1.0 
Total volume, m/  ........................  1.4  i .4  i .4  1.4 
If inhibitory activity was demonstrated, the rabbit received 1.0 ml injections of vaccine each 
week and was bled weekly as long as acceptable antiserum was produced. If serum-neutral- 
izing capacity was low or not present at the first postimmunization bleeding, the rabbit was 
continued on thrice weekly injections for an additional 4 wk, at which time its serum was re- 
tested for inhibitory antibodies. Preimmunization serum was obtained from most rabbits 
and tested for inhibition of the serum opacity reaction of the immunizing strain. 
Preparation of Enzyme for Serum  Opacity Inhibition  Tests.--Either merthiolate-treated 
cells or desoxychoiate extracts of a streptococcal cell wall and membrane fraction were satis- 
factory as a source of enzyme for serum opacity inhibition tests. To prepare cells, a strain was 
inoculated into 25 ml Todd-Hewitt broth which was incubated at 37°C for 16-18 hr. 1 ml of 
1% merthiolate solution was added to the overnight broth culture. The cells were harvested 
by centrifugation, washed twice in saline, and thoroughly suspended in 5 ml of 0.9% saline. 
After the addition of two drops of 1% merthiolate, the cells were stored at 4°C. No loss of 
activity was noted after storage for 7 days at 4°C. To prepare soluble desexycbolate extracts 
(4), an overnight growth of cells at 37°C in 200 ml Todd-Hewitt broth was collected by cen- 
trifugation, washed three times in 0.9% saline,  and resuspended in 7 ml of saline. After com- 
plete disruption of the cells in a  Mickle disintegrator, the cell wail-membrane fraction was 
collected by centrifugation at 20,000 g and washed twice in 0.9% saline. The ceil wall-mem- 
brane fraction was thoroughly suspended in 2--4 ml of a  1% sodium desoxycholate solution 
and incubated overnight at 4°C. A clear supematant fluid containing activity was obtained 
after centrifugation at 20,000 g. No appreciable loss of activity was evident after storage of this FRANKLIN  H.  TOP~ JR.~  AND  LEWIS  W.  WANNAMAKER  1017 
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soluble enzyme in 1% desoxycholate solution at --20°C for 3 months. Appropriate dilutions 
of both cells and desoxycholate extracts were made in 0.9~Vo saline from the stock enzyme 
preparation immediately prior to use in serum opacity inhibition tests. 
Mea,~ueemcn~ of Serum Opad~y InkibiSbm.--As detailed in Table I, four tubes containing 
the materials indicated were used to measure inhibition for each strain. Enzyme-containing 
dilutions and rabbit serum, both immune and nonimmune, were preincubated at 37°C  for 
15 rain prior to the addition of the horse serum. After the addition of 1.0 ml horse serum and 
1 drop of a  1~o merthiolate solution,  the contents of all  tubes were thoroughly mixed and 
incubated  at  37°C.  After  overnight  incubation,  1.4 mi  of  0.90/0 saline  was  added  to 
each  tube,  the  contents  of  each  tube  were  thoroughly  mixed,  and  each  tube  was 
centrifuged  to  remove  residual  cells.  The  optical  density  of  the  supernatant  fluid 
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Dilution of Stondord Ceil Suspensions 
Fxo.  1. Serum opacity produced by various amounts of cell suspensions from several dif- 
ferent strains of Group A streptococci. 
of  each  tube was  measured  at a  wave length  of  475  m#  in  a  Coleman Junior  Spectro- 
photometer  using  optically  matched  10  X  100  mm  glass  tubes.  The  superna- 
tant of tube II was used as a blank for the supernatant of tube I, and the difference in optical 
density (AODas) between these tubes represents the serum opacity produced by the amount 
of enzyme incubated in the system containing nonimmune serum. The supernatant of tube 
IV was used as a blank for the supernatant of tube HI and the AOD4~5 of these tubes repre- 
sents the serum opacity produced by the same amount of enzyme as in tube I  after prein- 
cubation with immune serum. The difference between the AOD475 of tubes I  and II and the 
AOD4~ of tubes HI and IV represents the amount of serum opacity inhibition by the immune 
serum. 
Fig. 1 shows the serum opacity produced by various comparable amounts of cell suspen- 
sions from several different strains of  Group A  streptococci.  Stock  cell suspensions of  six 
different strains were adjusted to a AOD~00 of 0.20. Twofold dilutions were made of these ad- 
justed stock suspensions and a 0.2 ml aliquot was incubated in a  system with 0.2 ml of non- 
immune rabbit serum and 1.0 ml horse serum for 16 hr at 37°C. The serum opacity produced 1018  SERUM  OPACITY REACTION Ol  ~ STREPTOCOCCUS  PYOGENES 
by comparable dilutions of ceils from these strains is plotted on the ordinate. A straight  line 
relationship between amount of cells added and the serum opacity produced is apparent up to 
a  AOD475 of 0.15. Above 0.15, the AOD476 is no longer directly proportional to the amount 
of cells added. This phenomenon was found to hold both for cell suspensions and for desoxy- 
cholate extracts  of the many serotypes tested  and probably represents  substrate  limitation 
in the system. Consequently for tests  of serum opacity inhibition, a predetermined dilution 
which would give a AOD475 after preincubation in nonimmune serum of 0.06--0.15 was used. 
To eliminate the effects of varying amounts of substrate in different lots of horse sera, one lot 
of serum was used for a series of experiments. 
Immune antiserum was used with experiments only if it was sufficiently potent to inhibit 
the amount of enzyme of the immunizing  strain which produced a AOD47u  of 0.10 after prein- 
cubation in nonimmune serum to a AOD4~5 of less than 0.02 after preincubation in antiserum. 
Antisera of this potency permitted  a clear distinction between inhibition and lack of inhibi- 
tion and were felt to be of sufficient strength  to permit detection of partial  inhibition of the 
serum opacity reaction, if such occurred. 
RESULTS 
The method of measuring the serum opacity reaction (SOR)  and inhibition 
of the reaction,  as described  above, has been  found to be quite  reproducible. 
When equivalent dilutions of enzyme of the same strain were used in a  series 
of duplicate determinations,  rarely did the AOD475 vary by more than 4-0.02. 
One variable  in the  system which cannot be readily eliminated  is  the rabbit 
serum  itself.  The  rabbit  serum  serves  not only as  a  source  of antibody but 
also as a  source of substrate  (arlipoprotein)  and  therefore contributes  to the 
opalescence which develops after incubation with streptococcal lipoproteinase. 
Variations in the al-lipoprotein content of the noDimmune and immune rabbit 
sera used can thus result in differences in the AOD,76 produced by the enzyme 
in  each  serum.  Sera  were  occasionally  encountered  which  produced  an  in- 
crease or decrease in nOD476 of greater than 0.02  (up to 0.04) when compared 
with  values  obtained  with  a  standard  noDimmtme  reference  rabbit  serum. 
Exclusion  of such sera  from the  following experiments  eliminated  variations 
in substrate  concentration  of rabbit  serum as a  cause of significant variation 
in the opacity produced. 
Inhibitory activity to the lipoproteinase produced by several strains  of dif- 
ferent  antigenic composition was not encountered  in the sera  of over 25  un- 
immunized rabbits tested.  Prelmmunization sera obtained from rabbits which 
later  developed inhibitory antibodies  to the lipoproteinase  of the immunizing 
strain invariably contained no inhibitory activity to this strain. 
Since preliminary experiments suggested the possibility of multiple  strepto- 
coccal  lipoproteinases  with  a  high  degree  of  strain  specificity,  antisera  to 
preparations  from  12  different  lipoproteinase-producing  strains  of  various 
T-agglutination patterns were examined in detail for their capacity to inhibit 
the  serum  opacity  reaction  of  strains  of  homologous  and  of  heterologous 
antigenic compositions with respect to their T, M, and R  antigens. FRANKLIN  H.  TOP,  JR.,  AND  LEWIS  W.  WANNAMAKEE  1019 
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Strains of T-Agglutination Pattern 2.-- 
A vaccine made from a prototype strain (T2/44/Rb4/91/1) of T-agglutina- 
tion pattern 2 produced suitable antiserum in all three rabbits immunlz~:i. A 
representative group of determinations of the influence of this immune rabbit 
serum on the serum opacity reaction produced by desoxycholate extracts of 
several homotypic and heterotypic strains is shown in Table II. It is evident 
that the serum opacity reaction produced by the three strains of T  pattern 2 
is completely inhibited after preincubation with the type 2  antiserum while 
the serum opacity reaction of strains of other T patterns is not inhibited by 
TABLE II 
Example of Serum Opacity Inkibition by a Type 2 Antiserum 
Strain 
CDC2 
3536 
6O90 
RL2415 
5856 
CDC28 
CV549 
6131 
AN124 
M type 
2 
NT* 
2 
NT 
49 
28 
NT 
25 
NT 
T pattern 
2 
2 
2 
8/2S/~np. 19 
14 
28 
5127/44 
8/25/imp. 19 
11 
OD4~  in  non- 
immune serum 
0.09 
0.15 
0.06 
0.11 
0.09 
0.09 
0.15 
0.15 
0.13 
OD4n in type 
2 antiserum 
0.00 
0.00 
0.00 
0.10 
0.09 
0.10 
0.13 
0.14 
0.13 
* NT, nontypable. 
this antiserum. The effects of this type 2 antiserum on a larger group of strains 
of various antigenic compositions  and from various sources  are summarized 
in Table HI. The SOR of all strains of T-agglutination pattern 2 was inhibited 
by the antiserum irrespective  of their production or lack of production of the 
type 2 M antigen or of the 28 R antigen as determined by precipitin tests. The 
serum opacity reaction of all 69 strains of heterologous  T-agglutination pat- 
terns was not inhibited by the type 2 SOR antisera. The serum opacity reac- 
tion of four representative T-2  strains, whose SOR was inhibited by type 2 
antisera, was not inhibited by the heterologous  SOR-inhibitory antisera sub- 
sequently described.  (One of the 12 antisera, CV238 antiserum, was obtained 
in sufficient quantity to permit the testing of all prototype strains used for 
immunization but not all other representative strains of heterologous  types.) 
Strains of T  Agglutination  Pattern 9.-- 
A vaccine prepared from a type 9 strain (Colindale 8316) produced suitable 
antisera in all three rabbits immunized. The results of S0R inhibition by these 1020  SERUM  OPACITY REACTION OF  STREPTOCOCCUS PYOGENES 
antisera are presented in Table IV. The type 9  antisera inhibited  the serum 
opacity reaction of all five strains of T  pattern 9, regardless of the presence 
or  absence  of  M  antigen,  but  did  not  inhibit  the  SOR  of 45  heterologous 
strains. The sermn opacity reaction of the 5 strains whose SOR was inhibited 
by the type 9 antisera was not inhibited by type 2 SOR-inhibitory antisera or 
by the other SOR-inhlbitory antisera to be described. 
TABLE III 
SOR Inhlbiaon by Antiserum from a Type 2 Strain (Tg1441Rb4/9I/3) 
Antigenic composition  of test strains*  Serum opacity  reaction 
Inhibited (No.  Not inhibited) 
M  of strains)  (No. of strains 
2 
NT 
2 
Heterologous types 
Heterologous types 
T  R 
2  NOg~ 
2  Neg 
2  28 
Neg 
28 
18 
3 
3 
0 
0 
0 
0 
0 
62 
7 
* Strains tested: 
Homologous T serotype: All homologous strains of groups I, H, and III (See Methods) 
plus: 
Strains positive for M 2 and negative for 28 R: From Minneapolis, strains 5862, 6020, 
6079, 6080, 6083, 6203, 6219, 6220, 6221, 6223, 6226; from St. Paul, strains AN688, AN957, 
AN959; from Colindale, strain 6090 (Col. 44]Rb4 Matt), 6118 (Col. 8322). 
Strains negative for M and negative for 28 R: From Minneapolis, strain 6198; from Colin- 
dale, strain 6092 (Col. T2/44/R6). 
Strains positive for M 2 and positive for 28 R: From Minneapolis, 4741; from St. Paul, 
AN835. 
Heterologo~ T serotypes: All heterologous strains of groups I, H, and HI (See Methods) 
pins: 
M-negative, T 11 strains: From Minneapolis, strain 6014, from Red Lake, strain RL583. 
~t Neg, negative for 28 R. 
Non-M-Typable  Strains  of T  Pattern  12.- 
Only non-M-typable strains  of T  pattern  12  produce  a  SOR;  M-typable 
type 12 strains have not, in our experience, produced this reaction (8). A vac- 
cine prepared from a  nontypable strain of T  pattern  12  (RL3124)  produced 
suitable antiserum in one of the three rabbits immunized. The results of SOP. 
inhibition by this antiserum  are shown in Table V.  The SOP.  of all six non- 
M-typable  strains  of T  pattern  12  was  inhibited  by  this  antiserum  which 
failed  to inhibit  the SOR  of 67  strains  of heterologous  serotypes. The SOP. 
of five of these T-12  strains was  examined for inhibition  by SOR-inhibitory 
antisera  prepared  against  heterologous  types.  The  activity  of  these  strains 
was not inhibited when tested with SOR-inhibitory antisera to types 2  and 9 
nor with the other antisera subsequently described. I~RANKLIN  H.  TOP,  JR.,  AND  LEWIS  W.  WANNAMAKER  1021 
Strains of T-Agglutination Pattern 14.- 
The T  pattern 14 is more complex than the three T  patterns previously con- 
sidered in that more than one M  type is associated with T  antigen 14. M  types 
14,  35,  49,  and  51  are included  in  this T  pattern  (11,  12),  although  recent 
studies have suggested that types 35  and 49 are identical  (13).  Strains of M 
types 14 and 51 have not been found to produce a serum opacity reaction (8). 
TABLE IV 
SOR InMblaon by Antiserum from a Type O  Strain  (6122) 
Antigenic composition  of test strains*  Serum opacity reaction 
Inhibited  (No. of  Not inhibited (No. 
M  T  strains)  of strains) 
9  9  1  0 
NT  9  4  0 
Heterologous serotypes  0  45 
* Strains tested: 
Homologous T  serotype: All homologous strains of groups I, H, and HI (See Methods). 
Heterologous T  serotypes:  All heterologous strains of groups II and HI (See Methods) 
TABLE V 
SOR Inhibition by Antiserum from Glossy Type 12 Strain  (RL3124) 
Antigenic composition  of test strains*  Serum opacity reaction 
Inhibited (No. of  Not inhibited (No. 
M  T  strains)  of strains) 
NT  12  6  0 
Heterologous serotypes  0  67 
* Strains tested: 
Homologous T  serotyp,: All homologous strains of groups I, II, and III (See Methods) 
plus M-negative, T 12 strain CV836B from Red Lake. 
HeY~ologous T serotype~: All heterologous strains of groups I, II, and HI (See Methods) 
plus M-negative, T 3/13/B3264 strain CV392 from Red Lake. 
A  vaccine made  from  the  prototype  type  49  strain  (B737/71/1)  with  T 
antigen  14 produced  suitable antiserum in  all rabbits immunized.  Results  of 
SOR inhibition with this antiserum are shown in Table VI. All SOR-positive 
strains  of T  pattern  14  showed  SOR  inhibition  with  B737/71/1  antiserum; 
these included 13 type 49 strains and two type 35 strains (typed in the labora- 
tory of Dr. Rebecca Lancefield), as well as 18 strains of this T  pattern which 
could not be  typed  by  type  49  M  antiserum  in  our  laboratory but  which 
reacted  with  a  specially absorbed 49 T-agglutination  serum when  examined 
in our laboratory or by W. R. Maxted (12). The SOR of three strains, originally 1022  SEI~U~  OPACITY REACTION" OF  STREPTOCOCCUS PYOGENES 
classified as M  type 49 but of a T  pattern  (5/27/44)  different from the proto- 
type 49  strain,  was not inhibited  by B737/71/1  antiserum,  and no SOR in- 
hibition was found with  this  antisermn  with  strains  of T  pattern  other than 
T-14. In further confirmation of their serologic specificity, the  serum  opacity 
reactivities  of five strains  which had  shown  SOR inhibition  with B737/71/1 
TABLE VI 
SOR Inhibition by Antiserum from Type 49 Strain  (B737/71/1) 
Antigenic composition  of test strains*  Serum opacity  reaction 
Inhibited (No. of  Not inhibited (No. 
M  T  strains)  of strains) 
49 
NT 
35 
?49 
Heterologous serotypes 
14 
14 
14 
5/27/44 
13 
18 
2 
0 
0 
0 
0 
0 
3 
66 
* Strains tested: 
Homologous T  serotype: All homologous strains  of groups I, II, and HI  (See Methods) 
plus: 
Strains positive for M 49: From Prague,  strains  6255 (Rock. Univ. A808), 6256 (Rock. 
Univ. A811), 6258 (Rock. Univ. A809), 6267 (Rock. Univ. A703); from Chile, strains  6260 
(Rock. Univ. B770), 6261 (Rock. Univ. B771), 6262 (Rock. Univ. B772), 6264 (Rock. Univ. 
B776), 6265 (Rock. Univ. B767), 6266 (Rock. Univ. B768). 
Strains negative for M: from Minneapolis, strain J. Scheuring; from Alabama (Dr. Hugh 
Dillon), strains  6085 (Ala. 585), 6085 (Ala. 3625), 6472 (Ala. 635), 6473 (Ala. 2115), 6474 
(Ala. 208S), 6476 (Ala. 2605), 6477 (Ala. 350S), 6478  (Ala. 380T), 6479 (AM. 3613), 6480 
(AM. 459T), 6481 (AM. 7195), 6482 (AM. 781T), 6483 (AM. 9165), 6484 (AM. 9665), 6485 
(Ala. 1258S). 
Strains  originally classified as M  35: From Rockefeller University,  strains  6304 (Rock. 
Univ. C135/22/0),  6305 (Rock. Univ. C171/100/3). 
Heterologous T serotypes: All heterologous strains  of groups I, H, and IH (See Methods) 
plus: 
Strains of T agglutination pattern 5/27/44, originally classified as M 49 but which could 
not be reconfirmed, as follows: From Red Lake,  6253 (Rock. Univ.  B738); from Prague, 
strain  6254 (Rock.  Univ.  A813); from Rockefeller University,  strain  6259 (Rock.  Univ. 
A834). 
antiserum were examined and found not to be inhibited by any of the heterol- 
ogous SOR-inhibitory antisera. 
Strains  of T-agglutination patterns  2, 9,  12, and  14 thus behaved similarly 
in  that  all  SOR-positive  strains  examined  from each  of the four different T 
patterns  produced  a  lipoproteinase  common to  other  strains  of the  same  T 
pattern,  but  anfigenically  distinct  from  the  lipoproteinases  of  strains  of 
heterologous patterns.  In the T-agglutination  patterns  to be considered next, FRANKLIN  H.  TOP~ JR.,  AND  LEWIS  W.  WANNAMAKER  1023 
the situation was more complex in that more than one class of strains could be 
distinguished  within the T  pattern  by means of antigenically distinct lipo- 
proteinase antigens. 
T-Agglutination  Patterns Associated with More than One A ntigenicall  y Distinct 
Lipoproteinase 
Strains  of T Pattern 8~25~Impetigo 19.-- 
A  vaccine prepared  from RL2415,  a  non-M-typable strain of T  pattern 
8/25/impetigo 19 (8/25/imp. 19), produced suitable antiserum in two of three 
TABLE VII 
SOR Inhibition by Antiserum from Nontypable 8/25/Imp. 19 Strain  (RI2415) 
Antigenic  composition  of test strains*  Serum opscity reaction 
Inhibited (No. of  Not inhibited (No. 
M  T  strains)  of strains) 
NT  8/25/imp. 19  6~  12§ 
8  8/25/imp. 19  0  3 
25  8/25/imp. 19  0  2 
Heterologous serotypes  0  59 
* Strains tested: 
Homologous T  serotype: All homologous strains of groups I, II, and III  (See Methods) 
plus: 
Strains negative for M: From Minneapolis, strains 3298 and 4297; from Red Lake, strains 
RL518, RL3020,  RL3050,  CV497A, CV560, CV786. 
M type 8 strain: From Minneapolis, strain 4297. 
Heterologous T serotypes: All heterologous  strains of groups I, II, and III (See Methods) 
plus: 
M-negative, T  11 strains listed in Table HI footnote. 
:~ Strains whose SOR is inhibited by RLPA15 serum: RL1533,  RL2415,  RL2717,  CV387, 
CV497A, CV677A. 
§ Includes three strains whose SOR is inhibited by AN730 antiserum (See Table VIII). 
immunized rabbits. The results of SOR inhibition with one of these antisera 
are presented in Table VII. The S0R of all 59 strains of T pattern other than 
8/25/imp.  19 was not inhibited by RL2415  antiserum. This  antiserum also 
failed  to inhibit the serum opacity reaction produced by strains of M  types 
8 and 25 which are  included in  the 8/25/imp.  19  T  agglutination pattern. 
The SOR of 6 of 18 non-M-typable 8/25/imp. 19 strains tested was however 
inhibited by the RL2415 antiserum. The serum opacity reactivities of four of 
the strains showing SOR inhibition by the RL2415 antiserum were examined 
for  inhibition  by  heterologous  SOR-inhibitory  antisera.  The  activities  of 
these strains were not inhibited by SOR-inhibitory antisera to strains of T 
patterns 2, 9, 12, and 14 nor by the antisera subsequently discussed, including 1024  SERUM  OPACITY  REACTION  OF  STREPTOCOCCUS  PYOGENES 
that made from a  second non-M-typable 8/25/imp.  19 strain, AN730.  SOR 
inhibition  by RL2415  antiserum was  thus  found  only among  strains  of T 
pattern 8/25/knp.  19, but not all strains of this T  pattern showed SOR inhi- 
bition by this antiserum. 
Satisfactory  antiserum  prepared  by  immunization  of  a  second  non-M- 
typable 8/25/imp.  19 strain  (AN730) whose SOR had not been inhibited by 
RL2415  antiserum was obtained in one of three ~mmunized rabbits.  As seen 
in Table VIII, AN730 antiserum inhibited the SOR of three of the 16 non- 
M-typable 8/25/imp.  19 strains tested; it did not inhibit the SOR of the six 
TABLE VIH 
SOR  InMbition  by  Antiserum from  Second Nontypable 8/gS/Imt~. 19  Strain (AN730) 
Antigenic composition of test strains*  Serum opacity reaction 
Inhibited (No. of  Not inhibited (No. 
M  T  strains)  of strains) 
NT  8/25/imp. 19  3~  13§ 
8  8/25/imp.  19  0  3 
25  8/25/imp. 19  0  2 
Heterologous serotypes  0  57 
* Strains tested: 
Homologous T serotypes: All homologous  strains of groups I, If, and HI except 5972 (See 
Methods) and all additional homologous strains listed in Table VII footnote except strain 
RL518. 
Heterologous T serotypea: All heterologous  strains of groups I, If, and HI (See Methods). 
Strains whose SOR is inhibited by AN730 antiserum are AN626, AN628, and AN730. 
§ Includes six strains whose SOR is inhibited by RL2415 antiserum (See Table VII). 
strains  whose  SOR  had  been  inhibited  by  RL2415  antiserum.  The  serum 
opacity reactions of M-typable strains in the 8/25/imp.  19 T  pattern (types 
8 and 25) tested were not inhibited by AN730 antiserum and the activities of 
strains of T  pattern other than 8/25/imp.  19 were likewise not inhibited. The 
serum  opacity reactions of the three strains  inhibited by AN730  antiserum 
were not inhibited by the antiserum to the 8/25/imp.  19 strain RL2415  de- 
scribed above nor by antisera to strains of heterologous types. 
Two  antigenically different lipoproteinases were thus found among strains 
of T  pattern 8/25/imp.  19.  Since the majority of non-M-typable strains  in 
this T  pattern as well as M  type 8 and 25 strains exhibited no SOR inhibition 
with either of the two antisera, it seems that several distinct strains as deter- 
mined by lipoproteinase antigen are found in this complex T  pattern. 
Strains of T-Agglutination Pattern 11.-- 
A  vaccine prepared from a  non-M-typable strain  of T-agglutination  pat- 
tern  11  (CV238)  produced acceptable  antiserum  in  two  of four immunized ~R.~NKLIN H.  TOP~ JR.,  AND LEWIS  W.  WANNAM.~K'~,~  1025 
rabbits. As shown in Table IX, the serum opacity reactions of 8  of 18 strains 
of T  pattern 11 were inhibited by CV238  antiserum, while the activities of all 
19  strains  of heterologous T  pattern  tested  were  not  inhibited.  The  serum 
TABLE IX 
SOR Inhibition  by Antiserum of Nontypable Strain of T Pattern 11 (CV23g) 
Antigenic  composition  of test strains*  Serum opacity  reaction 
Inhibited (No. of  Not inhibited  (No. 
M  T  strains)  of strains) 
11  11  0  1~ 
NT  11  8§  9 
Heterologous serotypes  0  19 
* Strains tested: 
Homdogoua T serotype: All homologous strains of groups I, H, and HI except 6123 (See 
Methods) plus: 
Strains negative for M: From Minneapolis, strain.q 5753, 5763, 6014; from St. Paul, strains 
AN102,  AN174,  AN322,  AN509,  AN733;  from Red Lake, strains RL583,  CV238, CV689. 
Heterologoua T serotypes: All heterologous strains of group I  (See Methods). 
:~ Tnhibited by Tll/54/3 antiserum (See Table X). 
§ Strains whose  SOR is inhibited by CV238 antiserum: 5763, AN124,  AN441,  CV238, 
CV595B, CV689, CV722, CV725A. 
TABLE X 
SOR Inkibition by Antiserum  of M  Type 11 Strain (Tll]54]3) 
Antigenic composition of test strains* 
M  T 
11  11 
NT  11 
Heterologous types 
Serum opacity  reaction 
Inhibited (No. of  Not Inibited  (No. 
strains)  of strains) 
0 
0 
0 
19§ 
63 
* Strains tested: 
Homologoua T serotype: All homologous strains of groups I, II, and HI (See Methods) and 
additional homologous strains of Table IX footnote, plus: 
Strain negative for M: From St. Paul, strain AN200. 
Heterologous T serotypes: All heterologous strains of groups I, II, mad HI (See Methods). 
:~ Strain whose SOR is inhibited is the immunizing strain (Tll/54/3). 
§ Includes eight strains whose  SOR is inhibited by CV238 antiserum  (See Table IX). 
opacity  reactions  of  five  strains  which  showed  SOR  inhibition  by  CV238 
antiserum were not inhibited by heterologous SOR-inhibitory antisera, includ- 
ing the antiserum made from a  M  type 11  strain described below. 
In order to investigate further this T-agglutination pattern,  a  vaccine was 1026  SERUM  OPACITY  REACTION  OP  STREPTOCOCCUS  PYOGENES 
prepared  from  the  prototype  type  11  M-producing  strain  (Tll/54/3).  An 
acceptable  antiserum was  produced in  one of three rabbits  immunized.  As 
shown in Table X, this antiserum only inhibited the SOR of the immunizing 
strain and did not inhibit the SOR of the 19 non-M-typable strains of T  pat- 
tern 11  (eight of which were inhibited by CV238 antiserum) nor the SOR of 
strains of heterologous T-agglutination patterns. The SOR of strain Tll/54/3 
was  not  inhibited  by  any  of  the  other  SOR-inhibitory  antisera  produced, 
including  CV238  antiserum.  Strains  of T  pattern  11  thus resemble those in 
TABLE XI 
SOR Inhibition by Antiser~ra  from Nontypable, 28 R-Negative, Strain of T Pattern 28 (AN632) 
Antigenic composition of test strains*  Serum opacity reaction 
Inhibition 
28 
28 
Heterologous 
Heterologous 
Neg 
28 
Neg 
28 
Complete 
(No. of strains) 
18 
0 
0 
0 
Partial 
(No. of strains) 
0 
7~ 
0 
0 
None 
(No. of strains) 
0 
0 
61 
3 
* Strains  tested: 
Homologous  T serotype:  All  homologous strains  of  groups I,  If,  and Iff (See  Methods) plus: 
Strains  negative  for  M  and R: From Minneapolis,  strains  5779,  6016,  6019;  from St. Paul, 
strains AN196, AN240, AN243, AN262, AN450, AN456, AN458, AN638, AN658. 
Strains negative for M and positive for 28 R: From Rockefeller  University, Strains 6273 
(Rock. Univ. A675/20/1) and 6274 (Rock. Univ. A800). 
Hegerologous  T serotypes:  All  heterologous  strains  of groups I, H, and HI (See Methods) 
plus: 
M-negative, T  11 strains  listed  in Table H  footnote. 
M-negative, T  12 strains:  From Red Lake, strains  Red Lake RL2802 and CV836B. 
All  seven strains  inhibited  by T28/150A/3 antiserum (See  Table XII). 
T  pattern 8/25/imp.  19, in that at least two distinct kinds of strains as deter- 
mined by specificity of lipoproteinase antigens exist within the T  pattern. 
Strains of T-Agglutination Pattern 28.-- 
Strains  wlth no  28  R  antigen:  Two of three rabbits  immunized produced 
suitable  SOR-inhlbitory  antiserum  after immunization  with  a  vaccine pre- 
pared from AN632, a non-M-typable strain of T pattern 28 whose acid extracts 
gave no precipitation with  28  R  antiserum.  As  shown in Table XI,  AN632 
antiserum completely inhibited the SOR of all 18 strains in the T pattern which 
gave no precipitation with 28 R antiserum. AN632 antiserum partially inhibited 
the SOR of seven strains of the same T  pattern which were shown to produce 
the 28 R  antigen. AN632  antiserum did not inhibit the SOR of 64 strains of FRANKLIN  H.  TOP~ JR.~  AND  LEWIS  W.  WANNAMAKER  1027 
heterologous  serotypes,  including  three  which  produced  the  28  R  antigen. 
The SOR of five of the strains whose SOR had been inhibited by AN632 anti- 
serum was not inhibited when tested with the other SOR-inhibitory antisera 
produced, including  that ihhibiting the SOR of a 28 R-producing strain (T28/ 
150A/3) described below. 
Strains with 28 R  antigen: Results with SOR-inhibitory antiserum produced 
by immunization of rabbits with strain T28/150A/3, a type 28 strain produc- 
ing the 28 R  antigen are shown in Table 3=11. The SOR of the 60 strains of 
heterologous  serotypes was  not  inhibited  by this  antiserum,  including  the 
three  strains  of heterologous type which produced the  28  R  antigen.  T28/ 
150A/3 antiserum completely inhibited the SOR of all  7 R-positive strains of 
TABLE XII 
SOR Inhibi~on by Antiserum from Type 28, 28 R-Positlve, StrMn (T281150A I3) 
Antigenic composition of test strains*  Serum opacity reaction 
Inhibition 
T 
28 
28 
Heterologous 
Heterologous 
R 
28 
Neg 
28 
Neg 
Complete 
(No. of strains) 
Partial 
(No. of strains) 
None 
(No. of strains) 
0 
18~ 
3 
57 
* Strains tested: 
Homologous T  serotype: All homologous strains shown in preceding Table (Table XI). 
He~rologous T serotypes: All heterologous strains of groups I, II, and HI (See  Methods). 
The SOR of all 18 strains is inhibited by AN632 antiserum (See  Table XI). 
T  pattern 28 (whose SOR had been partially inhibited by AN632 antiserum), 
but did not inhibit the SOR of any of the 18 R-negative strains of T  pattern 
28 (whose SOR had been completely inhibited by AN632 antiserum).  Five of 
the strains whose SOR was inhibited by T28/150A/3  antiserum were tested 
with  the  other  inhibitory  antisera  produced.  The  SOR  of these strains was 
unaffected by these antisera  with  the exception of A.N632 antiserum  which 
resulted in partial inhibition. 
A  one-way partial cross-reaction between lipoproteinase antigens was thus 
found in the two groups of strains (28 R-producing and non 28 R-producing) 
of T pattern 28. This cross-reaction may perhaps best be explained by a shared 
secondary  antigenic  determinant,  although  the  alternative  possibility  that 
more than one lipoproteinase is produced by the two groups of strains and that 
strains of both groups share one of these antigens could not be disproved. The 
peculiar  characteristics  of  lipoproteinase  antigens  render  classic  absorption 1028  SERUM  OPACITY REACTION OF STREPTOCOCCUS PYOGEArES 
techniques  difficult  in  that  antigen  is  extracted  from  the  absorbing  strain 
into  the  antiserum  where  it  produces  a  serum  opacity  reaction  during  the 
absorption process and reduces the sensitivity of subsequent  SOR-inhibition 
tests with the absorbed antisermn.  Strains in the T-agglutination pattern 28 
thus  appear  to  produce  two  lipoproteinases which  are  antigenically related. 
A  similar finding was apparent among strains in the T-agglutination pattern 
5/27/44. 
TABLE XIII 
SOR Inkihition by Antiserum  from Nontypable 5/27/44 Strain (CV549) 
Antigenic composition of test strains*  Serum opacity reaction 
Inhibition 
M  T 
NT 
27 
Heterologous serotypes 
5/27/44 
5/27/44 
Complete 
(No. of strains) 
4~ 
0 
0 
Partial 
(No. of strains) 
5§ 
1§ 
0 
None 
(No. of strains) 
9 
0 
63 
* Strains Tested: 
Homologous T Serotype: All homologous strains of groups I, II, and III (See Methods) 
plus: 
Strains of T agglutination pattern 5/27/44 which were negative for M: From Minneapolis, 
strains 6401 and  6344; from St. Paul, strains 6337, AN1275, AN1279, AN1600, AN1617; 
from Colindale, strain 6134 (Col. 100082). 
Strains of T agglutination pattern 5/27/44, originally classified as M 49 but which could 
not be reconfirmed: Strains 6253 and 6259 (See Table VI footnote). 
Heterologous T Serotypes: All heterologous strains of groups I, II, and III (See Methods). 
Strains whose SOR is completely inhibited by CV549 antiserum: RL3010B, RL3146, 
CV549, CV760A. 
§ Strains whose SOR is partially  inhibited by CV549 antiserum:  5937, 6134, RIA034, 
CV822B, AN586, CDC27. 
Strains of T-Agglutination Pattern 5/27/44.-- 
The  results  of  SOR  inhibition  by  antiserum  produced  against  a  non-M- 
typable strain of T  pattern 5/27/44  (CV549)  are shown in Table XIII. This 
antiserum was found to inhibit completely the SOR of four strains of T pattern 
5/27/44  and  partially  the SOR  of six other  strains  of this T  pattern.  Nine 
5/27/44  strains showed  no inhibition  with  CV549  antiserum nor did  the 63 
strains of heterologous T  pattern tested. The serum opacity reactions of three 
strains of T  pattern 5/27/44 whose SOR had been inhibited by CV549  anti- 
serum were not inhibited when tested with heterologous SOR antisera. 
Another  antiserum  was prepared by immunization with  a  second 5/27/44 
strain  (RL3034),  a  strain whose SOR had been partially inhibited by CV549 J~RANKLIN  H.  TOP~ JR.,  AND  LEWIS  W.  WANNAMAKER  1029 
antiserum. As is shown in Table XIV, RL3034 antiserum inhibited the SOR 
of three of the 5/27/44 strains tested. The SOR of all of these strains had been 
partially inhibited by CV549  antiserum. The SOR of the remaining 5/27/44 
strains  (including four whose SOR had been completely inhibited by CV549 
antiserum)  and the SOR  of strains  of heterologous T  patterns were not in- 
hibited by RL3034 antiserum. The serum opacity reactions of the three strains 
whose activities were inhibited completely by RL3034 antisermn and partially 
by CV549 antiserum were not inhibited by the other SOR-inhibitory antisera. 
TABLE  XIV 
SOR Inkibit~,~n by Antiserum from Second Nontypable 5/27/44 Strain (RL3034) 
Antigenic composition of test strains*  Serum opacity reaction 
Inhibition 
M  T 
NT 
27 
Heterologous serotypes 
5/27/44 
5/27/44 
Complete 
(No. of strains) 
2~ 
o 
Partial 
(No. of strains) 
None 
(No. of strains) 
15§ 
o 
63 
* Strains Tested: 
Homologous T Serotype: All homologous strains in preceding table (Table XIII) except 
strain 6134. 
Helerologous T Serotypes: All heterologous  strains of groups I, II, and III (See Methods). 
Strains inhibited by RL3034 antiserum were: RL3034, CV822B, CDC27, all of which 
are partially inhibited by CV549 antiserum (See  Table XIII). 
§ Includes the four strains from Table XIII whose SOR is completely  inhibited by CV549 
antiserum and the following  two strains which are partially inhibited by CV349 antiserum: 
5937, AN586. 
DISCUSSION 
Antisera  prepared  by  the  immunization  of  rabbits  with  crude  Group  A 
streptococcal cell wall-cell membrane fractions containing lipoproteinase ac- 
tivity have been shown to inhibit the serum opacity reaction (SOR) produced 
by the ~mmunizing strain. These antisera have been found also to inhibit the 
SOR of all or some strains homologous with respect to their T  antigens, but 
they did not inhibit the SOR of strains heterologous with respect to T  or M 
antigens.  SOR inhibition by the antisera has been demonstrated using both 
ceU-associated  and  soluble  enzyme.  12  antigenicaUy  different  streptococcal 
Hpoproteinases have been identified,  and each of the enzymes showed some 
association with serotype, as determined by M  and T  antigens. 
With respect to T  antigens, a distinct lipoproteinase antigen was found only 
among  strains  in  a  single T-agglutination pattern.  In  some T  patterns,  i.e. 1030  SERIY~ OPACITY REACTION OF STREPTOCOCCUS PYOGEIN-ES 
T  patterns  2,  9,  12,  and  14,  all  strains  of a  given T  pattern  produced im- 
munologically indistinguishable  lipoproteinase antigens.  In other T  patterns, 
i.e. T patterns 11, 28, 8/25/imp. 19, and 5/27/44, more than one class of strain 
could be differentiated by distinct lipoproteinase antigens within a T  pattern. 
With respect to M  antigens, the majority of strains which produce a lipo- 
proteinase  are untypable or difficult  to type by the precipitin  method.  We 
were only able to investigate strains of two M  types, types 2 and 49, for spe- 
cific lipoproteinase  antigens.  A  single  lipoproteinase  antigen  was invariably 
associated with each of the two M  antigens.  Each of the llpoproteinase anti- 
gens was found  also in  the non-M-typable  strains  of  the  corresponding  T 
pattern 2 and T pattern 14, respectively. 
It should be emphasized that  the vaccines and  enzyme preparations  used 
in these experiments were relatively crude. Since antisera were raised against a 
cell  wall-cell membrane  fraction  of streptococci,  they undoubtedly contain 
antibodies to other streptococcal antigens besides lipoproteinase.  Furthermore, 
desoxycholate extracts containing  lipoproteinase also contain  other antigens. 
A  desoxycholate extract  of strain  CV238  when tested against  antisera  from 
rabbits ~rnmunized with that strain produced three distinct lines in gel diffusion. 
In  view of the multiplicity  of antigens  contained  in  desoxycholate extracts 
and  the multiplicity of antibodies in  these antisera,  it  seems appropriate  to 
compare  some  of  the  characteristics  of  lipoproteinase  with  those  of  other 
known  streptococcal antigens  with  some  specificity--the M, T, and R anti- 
gens- in order to examine the question of whether these antigens are identical 
with or distinct from streptococcal llpoproteinase. 
Variation  in SOR production between strains  containing  identical T  anti- 
gens suggests that the T antigen and lipoproteinase antigen are distinct. Thus, 
in T-12  strains,  the occurrence of a  single T  antigen in both variants of the 
same strain, one of which produces lipoproteinase and one of which fails to pro- 
duce this enzyme, demonstrates that the T antigen and llpoproteinase antigen 
are separable by selection of variants  (8).  As  a  second example,  M  type 4 
strains produce lipoproteinase whereas types 24, 26, 29, and 46 strains do not 
(8)  despite a  serologically  indistinguishable  4-24  T  antigen  in  these  strains 
(19). 
The 28 R  antigen also appears to be distinct, both in serological  specificity 
and strain distribution, from the lipoproteinase antigen. Antiserum inhibitory 
to the SOR of a type 2 strain which produced the 28 R antigen did not inhibit 
the SOR of a 28 R-producing type 28 or type 48 strain. This antiserum inhibited 
the SOR of strains of T-agglutination  pattern 2 regardless of the presence or 
absence of the 28 R antigen in these strains. Furthermore, antiserum inhibiting 
the SOR of a 28 R-producing type 28 strain did not inhibit the SOR of a type 
2 or a type 48 strain producing this antigen. Despite a common 28 R  antigen 
in  these  three  strains,  they each produce  an  antigenically distinct  lipopro- I~ANKLIN  H.  TOP~ JR.,  AND  LEWIS  W.  WANNAMAKER  1031 
teinase.  Furthermore,  although a  specific  28  R  antiserum  produced  strong 
precipitation with extracts of these type 2, type 28, and type 48 strains, the 
same antiserum did not inhibit the SOR of any of these three strains. 
Evidence of a  difference in strain distribution between lipoproteinase and 
M  antigens is derived from our experience (8)  and that of others (6,  7) with 
strains of T-agglutination pattern 12. While M-typable type 12  strains do not 
produce  lipoproteinase,  naturally  occurring  M-negative  strains  and  glossy 
variants of type 12 strains regularly produce lipoproteinase. This inverse re- 
lationship between lipoproteinase and type 12 M  production among strains of 
this T-agglutination pattern suggests that the two antigens are distinct.  As 
TABLE XV 
Charaderistivs of M, T, and R Anggens and Lipoproteinase 
Characteristic  M Antigen  T Antigen  28 R Antigen  Lipoproteinase 
Digestion with: 
Trypsin 
Pepsin 
Streptococcal 
proteinase 
Boiling (pH 2.0) 
Extractable in: 
Desoxycholate 
Serum 
Sensitive (15)~t 
Sensitive (15) 
Sensitive (15) 
Resistant (15) 
No§ 
No 
Resistant (14) 
Resistant (14) 
Resistant (14) 
Sensitive 
No 
No 
Resistant* (16) 
Sensitive (16) 
Resistant (16) 
Partially re- 
sistant (16) 
m 
No 
Sensitive (4) 
Sensitive (4) 
Resistant (4) 
Sensitive:~ 
Yes (4) 
Yes (4) 
* 3 R differs  from 28 R in that it is sensitive to trypsin (18). 
~t Figures  in parentheses refer to bibliography. 
§ Top, F. H., Jr. Unpublished observations. 
a  second example, type 2-typing antiserum containing antibodies to the type 
2  M  antigen (as demonstrated both by precipitin reaction  and bactericidal 
tests)  failed to inhibit the SOR  of the immunizing strain.  That this serum 
contains antibodies  to  the  M  antigen in  good quantity but  no  detectable 
antibodies to lipoproteinase is evidence that the two antigens are immuno- 
logically different. 
Apart from these differences in strain distribution and immunological spe- 
cificity which  distinguish  the  streptococcal  lipoproteinase  from  previously 
well-established cellular antigens of Group A  streptococci, observations from 
other directions suggest  that  the lipoproteinases  have  properties  which  are 
not  uniformly  shared  by  other  streptococcal  cell-associated  antigens.  In 
Table XV, certain  characteristics of the M, T, and R  antigens of Group A 
streptococci,  as described by Lancefield and Dole  (14)  and Lancefield and 1032  SERU~  OPACITY REACTION OF STREPTOCOCCUS PYOGEIqES 
Perlman  (15,  16),  are compared with  those for lipoproteinase,  as described 
by Hill and Wannamaker  (4). It is well to consider  that in the above studies 
the M, T, and R  antigens were detected by precipitin tests whereas lipopro- 
teinase was detected by its capacity to produce opalescence  in serum.  Lipo- 
proteinase differs from the M  antigen in its resistance to digestion with strep- 
tococcal proteinase, its lability to heat at pH 2, and its extractability by serum 
and desoxycholate solution.  Lipoproteinase differs from the T  antigens in its 
sensitivity to digestion with trypsin and pepsin  and  in its extractability by 
serum and desoxycholate. It differs from the 28 R  antigen in its sensitivity to 
digestion with trypsin and in its extractability by serum. Moreover, the M, 
T, and R  antigens are surface antigens which appear to be associated with or 
attached  to the  streptococcal cell wall,  whereas available  evidence suggests 
that  the cell-bound lipoproteinase is associated predominantly  with  the cell 
membrane fraction (4). Therefore, on the basis of lines  of evidence of several 
different kinds,  it  seems likely that  lipoproteinase  is  distinct  from  the  M, 
T, and R  antigens and that this enzyme represents a fourth Group A strepto- 
coccal antigen with rather  remarkable  serological  specificity with respect to 
strain. 
The  production  of  immunologically  distinct  lipoproteinase  antigens  by 
strains of Group A streptococci currently difficult  to type by the M precipitin 
method may provide a  convenient tag for their more precise identification. 
Antiserum  inhibiting  lipoproteinase  has  already  proved quite useful in  our 
laboratory in the identification  of presumed type 49  strains  associated with 
acute glomerulonephritis,  many of which have been difficult to type with type 
49  M  antiserum.  In  serotypes which produce lipoproteinase  and  for which 
reasonably acceptable M  typing antisera are available, i.e.  type 2  and  type 
9, a distinct lipoproteinase antigen was invariably found to be associated with 
a  distinct  M  and  T  antigen.  Whether  the multiple  distinct  lipoproteinase 
antigens  identified  among  strains  with  certain  T  patterns  such  as  11  and 
8/25/imp. 19 will also be found to be associated with distinct M  antigens will 
only be determined by further investigations of the M antigens in these strains. 
Thus,  whereas the absence of lipoproteinase production was previously used 
as an indication of strains for which it might be profitable to explore the pos- 
sibility of new M  types (17),  the presence of lipoproteinases of different im- 
munological specificity among strains in the same complex T pattern suggests 
a  further  useful method of identifying discrete strains  within  these patterns 
which could then be investigated for M  antigens. 
In  view of  the  strain  specificity of  the  streptococcal lipoproteinases,  the 
antigenicity of these enzymes in humans as suggested by the reports of Krum- 
wiede (2) and Rowen (5) deserves more intensive study.  If further  investiga- 
tions confirm  the antigenicity of lipoproteinase in humans,  the enzyme may 
prove  to  be  a  convenient  antigen  for  the  determination  of  strain-specific 
antibodies  to  strains  whose M  antigens  are  currently  difficult  to  identify. FRANKLI~  H. TOP, JR.,  AND  LEWIS W. WANNAMAKER  1033 
SUMMARY 
Investigation  into  the  antigenicity  of  streptococcal  lipoproteinase  has 
revealed  the  existence  of multiple,  immunologicaUy distinct  enzymes.  Each 
lipoproteinase identified was found  to be strain specific in  that it was found 
only in  strains  of a  particular T-agglutination pattern.  In some T  patterns, 
all streptococci of that T  pattern which were examined shared a common lipo- 
proteinase antigen. In other T  patterns,  strains which  produced antigenically 
different lipoproteinases were identified. Evidence that the lipoproteinase anti- 
gen is distinct from other well-established cellular antigens of Group A strepto- 
cocci  has: been  presented.  The production  of this  strain-specific  enzyme by 
strains currently difficult to type by the standard M  precipitin method may 
facilitate more precise identification of these strains and a better assessment of 
their role in  the pathogenesis  of Group A  streptococcal infections and  their 
sequelae. 
It is a pleasure to acknowledge the capable technical assistance of Mrs. Joyce Tigner. 
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